How Janssen optimizes the stability of a therapeutic mAb

December 13, 2022

Discover how Janssen improved the stability of a promising prostate cancer targeting mAb.

You’ll learn about:

  • Why it is important to optimize stability measurements of a therapeutic mAb
  • How chemical stability offers useful insight into the developability of a mAb
  • What additional parameters Janssen evaluated to determine which enhanced mAb construct was the best option for further development

Why it’s important for therapeutic mAb optimization:

Therapeutic mAbs are often developed from assays that optimize their ability to bind a target of interest; however, the mAbs developed from this method are not always easy to purify or stable enough to reach clinical relevance.

Therefore, it’s critical to improve the stability of the mAb for clinical trials and long-term storage without losing the ability to bind to the target of interest. Janssen’s approach relies on chemical stability screens of a vast array of constructs modified from the parent mAb to find the best candidate for further development.

Want to know about high precision tools for the combined characterization of thermal and colloidal stability of biologics? Learn more about Prometheus Panta

Previous
Select the best biologics candidates with high-quality, multi-parameter stability characterization
Select the best biologics candidates with high-quality, multi-parameter stability characterization

Up next
Use stability profiling to build more effective gene therapy vectors with Prometheus Panta
Use stability profiling to build more effective gene therapy vectors with Prometheus Panta

Ready to tackle your challenging stability characterizations?

Discover tools